Skip to main content
Paul Paik, MD, Oncology, New York, NY, Memorial Sloan Kettering Cancer Center

PaulKPaikMD

Oncology • New York, NY

Thoracic Cancer

Physician

Request Appointment

Overview of Dr. Paik

Dr. Paul Paik is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. He received his medical degree from Weill Cornell Medicine and has been in practice 12 years. Dr. Paik accepts several types of health insurance, listed below. He is one of 465 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. He has more than 90 publications and over 500 citings.

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2008 - 2011
  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2005 - 2008
  • Weill Cornell Medicine
    Weill Cornell MedicineClass of 2005

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2021 - Present
  • NY State Medical License
    NY State Medical License 2008 - 2025
  • NJ State Medical License
    NJ State Medical License 2018 - 2025
  • American Board of Internal Medicine Medical Oncology

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping Mutations  
    Paul K Paik, Xiuning Le, The New England Journal of Medicine
  • PD-L1 Expression, Tumor Mutational Burden, and Response to Immunotherapy in Patients with MET Exon 14 Altered Lung Cancers  
    G J Riely, J Dienstag, C Mrad, J K Sabari, M G Kris, K C Arbour, D F Halpenny, N Rekhtman, R Chen, A J Plodkowski, P K Paik, B T Li, I Bergagnini, M D Offin, C M Rudin..., Annals of Oncology
  • YES1 Amplification Is a Mechanism of Acquired Resistance to EGFR Inhibitors Identified by Transposon Mutagenesis and Clinical Genomics  
    Emmet J Jordan, Helena A Yu, Yelena Y Janjigian, Mark G Kris, Paul K Paik, Jamie E Chaft, Lu Wang, Gregory J Riely, Proceedings of the National Academy of Sciences

Lectures

  • Targeting NFE2L2/KEAP1 mutations in advanced NSCLC with the TORC1/2 inhibitor TAK-228. 
    2019 ASCO Annual Meeting - 6/1/2019
  • Phase II study of tepotinib in NSCLC patients with METex14 mutations. 
    2019 ASCO Annual Meeting - 6/1/2019
  • Targeting NFE2L2 mutations in advanced squamous cell lung cancers with the TORC1/2 inhibitor TAK228. 
    2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018

Authored Content

  • Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping MutationsMay 2020
  • Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping MutationsMay 2020
  • Tepotinib in Non–Small-Cell Lung Cancer with MET Exon 14 Skipping MutationsMay 2020

Press Mentions

  • MET Mutation Inhibitor Associated with Tumor Reductions in NSCLC
    MET Mutation Inhibitor Associated with Tumor Reductions in NSCLCJune 26th, 2020
  • Paik Explains the Rationale for the Second-Line Standard for Patients with Squamous NSCLC
    Paik Explains the Rationale for the Second-Line Standard for Patients with Squamous NSCLCMay 17th, 2019
  • OncLive® Hosts State of Science Summit™ on Advanced Non-Small Cell Lung Cancer
    OncLive® Hosts State of Science Summit™ on Advanced Non-Small Cell Lung CancerApril 5th, 2018
  • Join now to see all

Hospital Affiliations

Insurance Accepted

  • Aetna Choice POS II
    Aetna HMO
    BCBS Blue Card PPO
    BCBS California PPO
    CIGNA HMO
    CIGNA Open Access
    CIGNA PPO
    Empire BCBS HMO
    Empire BCBS PPO
    GHI PPO
    Great West PPO
    Humana ChoiceCare Network PPO
    MVP Healthcare PPO
    Oxford Health Freedom
    Oxford Health Liberty
    United Healthcare - Direct Choice Plus POS
    United Healthcare - Direct Options PPO
  • Please verify your coverage with the provider's office directly when scheduling an appointment

Dr. Paul Paik, Dr. Paul Paik, MD, Dr. P Paik, Dr. Paul K Paik